Results 131 to 140 of about 6,967 (165)

What is the Appropriate Dose of Tolvaptan in ADPKD?

Kidney International Reports
Dahl, Neera K., Torres, Vicente E.
openaire   +2 more sources

Association of Early Tolvaptan Treatment and Length of In Hospital Stay in Elderly Patients with Acute Decompensated Heart Failure. [PDF]

JMA J
Suzuki S, Kimura K, Yoda N, Fuchida A, Kanzaki Y, Maruyama T, Hashizume N, Kozuka A, Motoki H, Yahikozawa K, Kuwahara K.   +10 more
europepmc   +1 more source

Predictors for Tolvaptan Treatment and Future Perspectives

International Heart Journal, 2016
openaire   +4 more sources

Treatment of hyponatremia: comprehension and best clinical practice. [PDF]

Clin Exp Nephrol
Sumi H, Tominaga N, Fujita Y, Verbalis JG, Electrolyte Winter Seminar Collaborative Group.   +4 more
europepmc   +1 more source

Tolvaptan and the role of kidney aquaporin-2 abundance in managing volume overload in patients with CKD. [PDF]

Clin Kidney J
Yan Y, Li XM, Yang Y, Wang FM, Liu H, Tang RN, Zhang XL, Liu BC, Wang B.   +8 more
europepmc   +1 more source

The Effect of Tolvaptan on Metabolism and Electrolyte Homeostasis in Patients with Heart Failure: A Systematic Review and Meta-Analysis. [PDF]

Rev Cardiovasc Med
Xiao Y, Chen Y, Zuo X, Mutalifu K, Chen X, Liu K.   +5 more
europepmc   +1 more source

Pharmacological Treatment of Ascites: Challenges and Controversies. [PDF]

Pharmaceuticals (Basel)
Lai JC, Dai J, Liang LY, Wong GL, Wong VW, Yip TC.   +5 more
europepmc   +1 more source

The Vasopressin Receptor Antagonist Tolvaptan Counteracts Tumor Growth in a Murine Xenograft Model of Small Cell Lung Cancer. [PDF]

Int J Mol Sci
Naldi L, Fibbi B, Polvani S, Cirillo C, Pasella F, Bartolini F, Romano F, Fanelli A, Peri A, Marroncini G.   +9 more
europepmc   +1 more source

A case report: pitfalls in antibacterial therapy with rifampicin for mechanical valve endocarditis-the king of drug interactions. [PDF]

Eur Heart J Case Rep
Honda R, Akazawa Y, Inoue K, Higaki T, Yamaguchi O.   +4 more
europepmc   +1 more source

A pharmacological chaperone stabilizer rescues the expression of the vast majority of pathogenic variants in a G protein-coupled receptor

Mighell TL, Lehner B.
europepmc   +1 more source